Literature DB >> 11718560

Defining the molecular basis of Arf and Hdm2 interactions.

B Bothner1, W S Lewis, E L DiGiammarino, J D Weber, S J Bothner, R W Kriwacki.   

Abstract

Understanding the interaction of Arf and Hdm2 has recently become a central issue in cancer biology. In response to hyperproliferative signals, p14(Arf) stabilizes p53 by binding to Hdm2 and inhibits the ubiquitination and subsequent proteosome-dependent degradation of p53. The medical importance of the Arf-Hdm2-p53 regulatory system is highlighted by the finding that either p53 or p14(Arf) are lost or modified in virtually all human cancers. Isolated Arf and Hdm2 domains are dynamically disordered in solution, yet they retain the ability to interact in vitro and in cellular assays. Upon binding, domains of both Arf and Hdm2 undergo a dramatic transition from disordered conformations to extended structures comprised of beta-strands. The presence of domains from both proteins are necessary and sufficient for the formation of the highly stable extended beta structures. We have mapped sites within Arf and Hdm2 that interact at a resolution of five amino acid residues using surface plasmon resonance. Surface plasmon resonance and circular dichroism spectropolarimetry confirm the presence of multiple interaction domains within each protein. Both p14(Arf) (human) and p19(Arf) (mouse) interact with Hdm2 through two short motifs present in their N termini. The Arf interacting region of Hdm2 is also composed of two short sequences located in the central acidic domain, between residues 235-264 and 270-289. The binding-induced structural transition is also induced by short peptides, 15 amino acids in length, that contain the binding motifs. Micro-injection and live cell imaging of proteins tagged with fluorescent labels was used to confirm the in vivo function of the interaction domains. Arf and Hdm2 thus appear to interact through a novel mechanism that exerts control over the cell division cycle. The novel molecular mechanism of interaction and the limited size of the protein domains involved provide opportunities for the development of anticancer therapeutics. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718560     DOI: 10.1006/jmbi.2001.5110

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  41 in total

1.  The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Authors:  Christian Kannemeier; Rong Liao; Peiqing Sun
Journal:  Mol Biol Cell       Date:  2007-04-11       Impact factor: 4.138

2.  Study on the spatial architecture of p53, MDM2, and p14ARF containing complexes.

Authors:  Andrej Savchenko; Mariya Yurchenko; Boris Snopok; Elena Kashuba
Journal:  Mol Biotechnol       Date:  2008-11-07       Impact factor: 2.695

3.  Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo.

Authors:  Sivashankar G Sivakolundu; Amanda Nourse; Simon Moshiach; Brian Bothner; Chimere Ashley; John Satumba; Jill Lahti; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2008-09-16       Impact factor: 5.469

4.  Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.

Authors:  Brittany Cross; Lihong Chen; Qian Cheng; Baozong Li; Zhi-Min Yuan; Jiandong Chen
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

5.  Expanding the proteome: disordered and alternatively folded proteins.

Authors:  H Jane Dyson
Journal:  Q Rev Biophys       Date:  2011-07-01       Impact factor: 5.318

6.  P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3.

Authors:  Abdessamad Zerrouqi; Beata Pyrzynska; Maria Febbraio; Daniel J Brat; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

7.  Autoactivation of the MDM2 E3 ligase by intramolecular interaction.

Authors:  Qian Cheng; Tanjing Song; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2014-05-19       Impact factor: 4.272

8.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  DNA damage response to the Mdm2 inhibitor nutlin-3.

Authors:  Rajeev Verma; Marc J Rigatti; Glenn S Belinsky; Cassandra A Godman; Charles Giardina
Journal:  Biochem Pharmacol       Date:  2010-02-15       Impact factor: 5.858

10.  ARF represses androgen receptor transactivation in prostate cancer.

Authors:  Wenfu Lu; Yingqiu Xie; Yufang Ma; Robert J Matusik; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.